Dissolve-E: AWMF Guideline Registry
0.2.0 - ci-build
Dissolve-E: AWMF Guideline Registry - Local Development build (v0.2.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:Composition ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "RecommendationAgainstBoneMarrowBiopsy"] ; #
fhir:meta [
( fhir:profile [
fhir:v "http://fhir.awmf.org/awmf.ig/StructureDefinition/recommendation"^^xsd:anyURI ;
fhir:l <http://fhir.awmf.org/awmf.ig/StructureDefinition/recommendation> ] )
] ; #
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\" dir=\"ltr\">Situationen mit Empfehlungen gegen eine Knochenmarkbiopsie</div>"^^rdf:XMLLiteral ]
] ; #
fhir:identifier ( [
fhir:use [ fhir:v "official" ] ;
fhir:system [
fhir:v "http://fhir.awmf.org/examples"^^xsd:anyURI ;
fhir:l <http://fhir.awmf.org/examples> ] ;
fhir:value [ fhir:v "RecommendationAgainstBoneMarrowBiopsy" ]
] ) ; #
fhir:version [ fhir:v "2022"] ; #
fhir:status [ fhir:v "final"] ; #
fhir:type [
( fhir:coding [
fhir:system [
fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ;
fhir:code [ fhir:v "Recommendation" ] ;
fhir:display [ fhir:v "Recommendation" ] ] )
] ; #
fhir:category ( [
( fhir:coding [
fhir:system [
fhir:v "http://fhir.awmf.org/awmf.ig/CodeSystem/cs-recommendation-synthesis-type"^^xsd:anyURI ;
fhir:l <http://fhir.awmf.org/awmf.ig/CodeSystem/cs-recommendation-synthesis-type> ] ;
fhir:code [ fhir:v "evidence-based" ] ;
fhir:display [ fhir:v "Evidence-based" ] ] )
] ) ; #
fhir:date [ fhir:v "2022-10-01"^^xsd:date] ; #
fhir:author ( [
fhir:l fhir:Organization/DGHO ;
fhir:reference [ fhir:v "Organization/DGHO" ]
] [
fhir:l fhir:PractitionerRole/UlrichDuehrsenDGIMFor018-038 ;
fhir:reference [ fhir:v "PractitionerRole/UlrichDuehrsenDGIMFor018-038" ]
] [
fhir:l fhir:PractitionerRole/DirkHellwigDGNFor018-038 ;
fhir:reference [ fhir:v "PractitionerRole/DirkHellwigDGNFor018-038" ]
] [
fhir:l fhir:PractitionerRole/ThorstenPersigehlDRGFor018-038 ;
fhir:reference [ fhir:v "PractitionerRole/ThorstenPersigehlDRGFor018-038" ]
] [
fhir:l fhir:PractitionerRole/LaleUmutluDRGFor018-038 ;
fhir:reference [ fhir:v "PractitionerRole/LaleUmutluDRGFor018-038" ]
] ) ; #
fhir:title [ fhir:v "Situationen mit Empfehlungen gegen eine Knochenmarkbiopsie"] ; #
fhir:relatesTo ( [
fhir:type [ fhir:v "part-of" ] ;
fhir:target [
a fhir:Canonical ;
fhir:v "http://fhir.awmf.org/awmf.ig/Composition/DiffuseLargeBCellLymphomaGuideline|2022"^^xsd:anyURI ;
fhir:l <http://fhir.awmf.org/awmf.ig/Composition/DiffuseLargeBCellLymphomaGuideline?version=2022> ]
] ) ; #
fhir:section ( [
fhir:code [
( fhir:coding [
fhir:system [
fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ;
fhir:l <https://fevir.net/resources/CodeSystem/179423> ] ;
fhir:code [ fhir:v "recommendation-statement" ] ;
fhir:display [ fhir:v "Recommendation Statement" ] ] ) ] ;
( fhir:section [
( fhir:extension [
fhir:url [
fhir:v "http://fhir.awmf.org/awmf.ig/StructureDefinition/ext-section-language"^^xsd:anyURI ;
fhir:l <http://fhir.awmf.org/awmf.ig/StructureDefinition/ext-section-language> ] ;
fhir:value [
a fhir:Code ;
fhir:v "de" ] ] ) ;
fhir:code [
( fhir:coding [
fhir:system [
fhir:v "http://fhir.awmf.org/awmf.ig/CodeSystem/cs-guideline-sections"^^xsd:anyURI ;
fhir:l <http://fhir.awmf.org/awmf.ig/CodeSystem/cs-guideline-sections> ] ;
fhir:code [ fhir:v "language" ] ;
fhir:display [ fhir:v "Language" ] ] ) ] ;
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\" dir=\"ltr\"><div><p>Bei Einsatz der PET/CT zur Stadieneinteilung soll bei kurativem Konzept in folgenden Situationen auf eine Knochenmarkbiopsie verzichtet werden:</p><ul><li>Nachweis einer Knochenmarkbeteiligung durch die PET/CT</li><li>Fortgeschrittenes Ausbreitungsstadium (Ann Arbor-Stadium III oder IV; <a>s. 5.2.3.1</a>)</li><li>Limitiertes Ausbreitungsstadium (Ann Arbor-Stadium I oder II) mit ‚bulky disease‘ (<a>s. 5.3.2.1.</a>) und/oder ≥ 1 ungünstigem Faktor des altersadjustierten ‚Internationalen Prognostischen Index‘ (IPI) (s. <a>5.3.1.2</a>).</li></ul></div></div>"^^rdf:XMLLiteral ] ] ] )
] ) . #
IG © 2024+ AWMF e.V.. Package awmf.ig#0.2.0 based on FHIR 6.0.0-ballot3. Generated 2026-03-19
Links: Table of Contents |
QA Report